59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.
2 citations
,
December 2022 in “Journal of Clinical Medicine” Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
February 2024 in “Journal of Education, Health and Sport” Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.